key: cord-0760184-82172qjf authors: Sørvoll, Ingvild Hausberg; Horvei, Kjersti Daae; Ernstsen, Siw Leiknes; Lægreid, Ingvild Jenssen; Lund, Svetlana; Grønli, Renathe Henriksen; Olsen, Magnus Kringstad; Jacobsen, Hege Karine; Eriksson, Anna; Halstensen, Anne Marie; Tjønnfjord, Eirik; Ghanima, Waleed; Ahlen, Maria Therese title: An observational study to identify the prevalence of thrombocytopenia and anti‐PF4/polyanion antibodies in Norwegian health care workers after COVID‐19 vaccination date: 2021-05-18 journal: J Thromb Haemost DOI: 10.1111/jth.15352 sha: 028a1197e409b549a1c37cadc019d1cc12d9219f doc_id: 760184 cord_uid: 82172qjf BACKGROUND: The COVID‐19 vaccine from AstraZeneca (AZD1222) is one of several vaccines introduced to provide immunity against SARS‐CoV‐2. Recently, more than 50 cases have been reported presenting a combination of thrombosis, thrombocytopenia, and remarkably high levels of anti‐platelet factor 4 (PF4)/polyanion antibodies post‐AZD1222 vaccination. Now linked to the vaccine, the condition is referred to as vaccine‐induced immune thrombotic thrombocytopenia. The European Medicines Agency still recommends vaccination with AZD1222, but several European countries have temporally paused and/or restricted its use because of the perceived risk of this severe side effect. Because there is no description of PF4/polyanion antibody testing in the clinical trials, knowledge about the prevalence of such antibodies in a vaccinated cohort is needed. OBJECTIVES: To investigate prevalence of thrombocytopenia and anti‐PF4/polyanion antibodies in a population recently vaccinated with AZD1222. PATIENTS/METHODS: Four hundred and ninety‐two health care workers recently vaccinated with the first dose of AZD1222 were recruited from two hospitals in Norway. Study individuals were screened for thrombocytopenia and the presence of anti‐PF4/polyanion antibodies with a PF4/PVS immunoassay. Side effects after vaccination were registered. RESULTS: The majority of study participants had normal platelet counts and negative immunoassay. Anti‐PF4/polyanion antibodies without platelet activating properties were only detected in six individuals (optical density ≥0.4, range 0.58–1.16), all with normal platelet counts. No subjects had severe thrombocytopenia. CONCLUSIONS: We found low prevalence of both thrombocytopenia and antibodies to PF4/polyanion‐complexes among Norwegian health care workers after vaccination with AZD1222. Massive vaccination campaigns using various anti-COVID vaccines have started around the world to bring COVID-19 pandemic to a halt. Among these, the AZD1222 (ChAdOx nCoV-19) vaccine from AstraZeneca has been shown to be effective and safe in preventing COVID-19. 1 This vaccine was widely administered to health care workers under the age of 65 years in Norway. Recently, a link between the AZD1222 and a rare thrombotic disorder has been reported by The European Medicines Agency (EMA) 2 with more than 50 cases reported in Europe. [3] [4] [5] The disorder has a resemblance to heparin-induced thrombocytopenia (HIT); however, it does not require heparin as a trigger, thus mimicking spontaneous autoimmune heparin-induced thrombocytopenia. 6 We recently reported this condition in five Norwegian health care workers presenting with venous thrombosis at unusual sites, and thrombocytopenia 7-10 days after receiving AZD1222. 4 At the Norwegian National Unit for Platelet Immunology, we revealed remarkably high levels of anti-platelet factor 4 (PF4)/polyanion antibodies in enzyme-linked immunosorbent assay (ELISA) in all five cases. Four of these cases also demonstrated platelet-activating properties in functional testing assay. This tentative vaccineinduced condition has been referred to as vaccine-induced immune thrombotic thrombocytopenia (VITT). Other groups have also reported several cases with very similar clinical presentation after AZD1222 vaccination. 3, 5 The pathogenesis of VITT is still unknown. Across Europe, millions of people aged 18 years or older have been vaccinated with AZD1222. Systemic adverse reactions are common, but rarely severe, 7 in contrast to the devastating VITT development that often has a fatal outcome. Several countries have put the vaccine on hold after the emergence of cases of these rare thrombotic events. The safety committee of EMA concluded after evaluation in March 2021 that the benefits of the vaccine in combating COVID-19 still outweigh the risk of side effects. Further, according to EMA, there is no evidence of product quality issues related to specific vaccine batches or manufacturing sites. 2 The safety studies report fewer cases of thrombosis than in unvaccinated controls. 7 In Norway, approximately 135 000 individuals have received AZD1222 since February 2021. 8 The VITT cases have raised concern that vaccinated individuals have a higher risk of development or boosting of anti-PF4/polyanion reactive antibodies. Platelet antibody testing has not been previously described in the intervention group or control group in the clinical phase 1/2/3 studies. 1, 9, 10 The aim of this study was to investigate the prevalence of thrombocytopenia and anti-PF4/polyanion antibodies in a population recently vaccinated with AZD1222, both to identify individuals that may be at risk of developing VITT, and to investigate the prevalence of apparently subclinical anti-PF4/polyanion antibodies. ELISA has been shown to reliably detect anti-PF4 antibodies associated with VITT, [3] [4] [5] and was thus used for antibody screening in this study. donors with no history of COVID-19 from the blood donation service (UNN) as a control group. Plasma and serum were also biobanked for further analysis related to the safety of this vaccine. Side effect data were reported on a questionnaire grading experienced symptoms, as fever, headache, vomiting, fatigue, cutaneous bleeding, malaise, and muscle and joint ache on a scale from 0 to 6. Demographic data were registered. Also, the participants reported use of medication such as paracetamol or ibuprofen in relation to vaccination. Whole blood was collected and processed by standard procedures for hematology and platelet immunology testing. Proportions and confidence intervals (CI) for descriptive data and side effects were calculated in SPSS Statistics 26 with 95% significance level (bootstrap method). GraphPad Prism 8.12 was used to create figures for platelet counts and ELISA OD values. Line represents median value, and whiskers 95% CI. Anti-PF4/polyanion reactive antibodies in high levels seem to be a defining feature of VITT, the devastating clinical picture recently described after AZD1222 vaccination. 4 The link between vaccination and antibody formation or boosting is unknown and determining the frequency of PF4/PVS antibodies in a vaccinated group compared to unvaccinated is an important contribution to investigate such an association. A total of 502 vaccinated health care workers were included in the study. Because of missing data, 10 individuals were excluded. The remaining 492 study participants were included in final data analysis. In the control group, 110 blood donors were included (Table 1 Our narrow inclusion window of 10-35 days postvaccination was selected to be able to detect both an immunological boosting of preformed antibodies, as well as a de novo anti-PF4/polyanion IgG response. There are limited data regarding the time range for antibody detection for autoimmune HIT, but for typical HIT the detection window is relatively short because these antibodies tend to disappear within 50-85 days. 13 Most participants reported fever, headache, fatigue, malaise, and muscle/joint ache ( However, because the entity emerged very recently with only a few cases reported worldwide, the condition may be underreported, and its true incidence is yet unknown. Perceived risk of severe side effects can lead to vaccine hesitancy in the general population, which may delay vaccine coverage. Vaccination is of utter importance in combating the COVID-19 pandemic. To earn public trust, gathering knowledge about serious adverse effects from vaccination is important to be able to make well-informed decisions regarding vaccine strategy. In conclusion, this is the first study to screen for anti-PF4/ polyanion antibodies in a population vaccinated with AZD1222. We did not find anti-PF4/polyanion platelet activating antibodies, nor severe thrombocytopenia in approximately 500 vaccinated participants. This suggests that both the natural occurrence and postvaccine de novo generation or boosting of such antibodies are rare. If the incidence of high-level anti-PF4/polyanion antibodies tentatively causing VITT is closer to the observed incidence of VITT, the number of individuals included in our observational study is clearly too low. Determining a low incidence would require F I G U R E 2 Anti-PF4/PVS reactive antibodies were detectable in six individuals (1.2%) in the vaccine cohort by ELISA. The highest OD value was 1.16, OD ≥0 .4 indicate presence of antibodies. OD, Optical density; PF4, platelet factor 4 F I G U R E 1 In total, only eight of the 492 vaccinated individuals (1.6%) had thrombocytopenia, with platelet count above 100 × 10 9 /L. Line represents median, error bars 95% confidence interval Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial Signal assessment report on embolic and thrombotic events (SMQ) with COVID-19 vaccine (ChAdOx1-S ents/prac-recom menda tion/signa l-asses sment -repor t-embol icthrom botic -event s-smq-covid -19-vacci ne-chado x1-s-recom binan t-covid_en Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination Pathologic antibodies to platelet factor 4 after ChAdOx1 nCoV-19 vaccination Autoimmune heparininduced thrombocytopenia Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials Heparin-induced multiple electrode aggregometry is a promising and useful functional tool for heparin-induced thrombocytopenia diagnosis: confirmation in a prospective study Platelet factor 4/ heparin antibodies in blood bank donors Temporal aspects of heparin-induced thrombocytopenia TA B L E 2 Self-reported side effects after vaccination Note: Categories of symptoms in questionnaire 0-6: none (0), mild (1-2), moderate (3) (4) , severe (5-6), any (1-6).